drugset
Drugs / ALVAC-HIV MN120TMG
last change Apr 2005 re-read 9 days ago

ALVAC-HIV MN120TMG

also known as vCP205

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Case Western Reserve University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Fogarty International Center of the National Institute of Health · Joint Clinical Research Center · Joint UN Programme on HIV/AIDS (UNAIDS)
+1 more · MRC/UVRI and LSHTM Uganda Research Unit

Trials 8

today NCT00000879 · Ph 1 NCT00007423 · Ph 1 NCT00001136 · Ph 1 NCT00000884 · Ph 1 NCT00000871 · Ph 2 NCT00001090 · Ph 1 NCT00000847 · Ph 1 NCT00001076 · Ph 1
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT00001076 ? → Dec 1997 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000847 ? → May 1999 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000879 ? → Apr 2005 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00001136 ? → May 2001 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000884 ? → Oct 2000 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00001090 ? → Oct 1999 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00007423 ? → Sep 2001 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00000871 ? → Jan 2000 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as ALVAC-HIV MN120TMG ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000847 ↗
7

NCT00000884 ↗

NCT00007423 ↗

NCT00001136 ↗

NCT00001076 ↗

NCT00001090 ↗

NCT00000871 ↗

NCT00000879 ↗
Known as vCP205 “recombinant canarypox vaccine ALVAC-HIV MN120TMG (vCP205)” NCT00001076 ↗
3

“ALVAC-HIV MN120TMG (vCP205)” NCT00000847 ↗

“ALVAC-HIV MN120TMG (vCP205)” NCT00000879 ↗

“ALVAC-HIV MN120TMG (vCP205)” NCT00007423 ↗
Modality Vaccine “Live Recombinant Canarypox ALVAC-HIV vCP205” NCT00000871 ↗
Route Intramuscular “Participants will undergo treatment intramuscularly” NCT00000884 ↗